1HM.F Adaptive Biotechnologies Corporation

Healthcare Biotechnology Frankfurt Exchange
25.97 EUR
Close of Nov 11, 2026
10.65 72.62
Market cap
EUR 4.20B
P/E
-
P/B
25.14x
ROE
-43.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 1HM.F undervalued?

Graham number

The Graham number of Adaptive Biotechnologies Corporation cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Adaptive Biotechnologies Corporation fundamental analysis

No fundamental analysis for Adaptive Biotechnologies Corporation yet.

Adaptive Biotechnologies Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are …

Full company profile